<div class="container">

<table style="width: 100%;"><tr>
<td>cm214_pfs</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Sample Reconstructed Data of CheckMate214 Study</h2>

<h3>Description</h3>

<p>The progression-free survival data reconstructed from the publication of the CheckMate214 study.
</p>


<h3>Usage</h3>

<pre><code class="language-R">data(cm214_pfs)
</code></pre>


<h3>Format</h3>

<p>A dataset containing 3 columns:
</p>

<dl>
<dt>time</dt>
<dd>
<p>the time-to-event variable (the time unit is month)</p>
</dd>
<dt>status</dt>
<dd>
<p>the event indicator (1=event, 0=censor)</p>
</dd>
<dt>arm</dt>
<dd>
<p>the treatment indicator (1=treatment, 0=control)</p>
</dd>
</dl>
<h3>Details</h3>

<p>This is a reconstructed patient-level data from the results reported by Motzer et al.(2018) &lt;doi:10.1056/NEJMoa1712126&gt;.
The data consists of 847 patients with previously untreated clear-cell advanced renal-cell carcinoma; 425 for the nivolumab plus ipilimumab group (treatment) and 422 for the sunitinib group (control).
</p>


<h3>Source</h3>

<p>Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
New England Journal of Medicine. 2018;378(14):1277-1290. &lt;doi:10.1056/NEJMoa1712126&gt;
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. &lt;doi:10.1186/1471-2288-12-9&gt;
</p>


</div>